Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade.
Eric J MillerTracy L RoseBenjamin L MaughanMatthew I MilowskyMehmet Asim BilenBradley C CarthonXin GaoSuthee RapisuwonQianqian ZhaoMenggang YuNeeraj AgarwalMatthew D GalskyPublished in: Cancer (2024)
High dose CTLA-4 blockade in patients with PD-1/PD-L1-resistant metastatic urothelial cancer has modest activity and is associated with treatment-related toxicity similar to prior reports.